Literature DB >> 28594749

CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.

Thomas Schachtner1, Maik Stein, Petra Reinke.   

Abstract

BACKGROUND: Detectable cytomegalovirus (CMV)-specific T cells in CMV-seronegative kidney transplant recipients (KTRs) have been attributed to an absence of circulating antibodies despite CMV sensitization. The diagnostic value of CMV-specific T cells, however, needs to be implemented in risk stratification for CMV replication.
METHODS: Three hundred twenty-six KTRs were studied and classified with respect to CMV serostatus and presence of CMV-specific T cells. Samples were collected pretransplantation, at +1, +2, and +3 months posttransplantation. CMV-specific T cells directed to CMV-IE1 and CMV-pp65 were measured by interferon-γ Elispot assay.
RESULTS: Nineteen (28%) of 67 D+R- KTRs showed pretransplant CMV-specific T cells. Although no differences were observed for CMV replication, KTRs with CMV-specific T cells presented with lower initial and peak CMV loads (P < 0.05). KTRs with decreasing/undetectable CMV-IE1-specific T cells pretransplantation and posttransplantation were at greatest risk of CMV replication. KTRs with stable/increasing CMV-IE1-specific T cells from pretransplantation to posttransplantation, however, showed low risk of CMV replication (P < 0.001). One hundred sixty-two (80%) of 203 R+ KTRs showed pretransplant CMV-specific T cells. Decreasing/undetectable CMV-IE1-specific T cells from pretransplantation and posttransplantation identified those R+ KTRs at increased risk of CMV replication (65/80 KTRs; 81%; P < 0.001).
CONCLUSIONS: Despite CMV prophylaxis, D+R- KTRs are at greatest risk of CMV disease. Our data suggest that monitoring CMV-specific T cell kinetics from pretransplantation to posttransplantation, particularly directed to CMV-IE1, offers superior risk stratification compared with CMV serostatus alone.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28594749     DOI: 10.1097/TP.0000000000001825

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  15 in total

Review 1.  Immune Monitoring for CMV in Transplantation.

Authors:  Michelle K Yong; Sharon R Lewin; Oriol Manuel
Journal:  Curr Infect Dis Rep       Date:  2018-03-14       Impact factor: 3.725

Review 2.  Utility of Cytomegalovirus Cell-Mediated Immunity Assays in Solid Organ Transplantation.

Authors:  Victoria G Hall; Atul Humar; Deepali Kumar
Journal:  J Clin Microbiol       Date:  2022-05-11       Impact factor: 11.677

Review 3.  Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation.

Authors:  Ajit P Limaye; Tara M Babu; Michael Boeckh
Journal:  Clin Microbiol Rev       Date:  2020-10-28       Impact factor: 26.132

Review 4.  New Developments in the Management of Cytomegalovirus Infection After Transplantation.

Authors:  Atibordee Meesing; Raymund R Razonable
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

5.  Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines.

Authors:  Suresh B Boppana; William J Britt
Journal:  Methods Mol Biol       Date:  2021

6.  Diagnostic performance of cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation: A PRISMA-compliant article.

Authors:  Yashi Ruan; Wei Guo; Sudong Liang; Zhen Xu; Tianli Niu
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

7.  Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients.

Authors:  Leila Amini; Tino Vollmer; Desiree J Wendering; Anke Jurisch; Sybille Landwehr-Kenzel; Natalie Maureen Otto; Karsten Jürchott; Hans-Dieter Volk; Petra Reinke; Michael Schmueck-Henneresse
Journal:  Front Immunol       Date:  2019-05-28       Impact factor: 7.561

Review 8.  Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update.

Authors:  Katya Prakash; Aditya Chandorkar; Kapil K Saharia
Journal:  Diagnostics (Basel)       Date:  2021-05-13

9.  Effect of Type of Dialysis on CMV-Specific CD8+ T Cells in Kidney Transplant Candidates.

Authors:  Jose Ramón Vidal-Castiñeira; Viviana Corte-Iglesias; Lucia Sobrino-Diaz; Sonia Pérez-Fernández; Santiago Melón; Carlos López-Larrea; Carmen Díaz-Corte
Journal:  Front Immunol       Date:  2019-07-19       Impact factor: 7.561

10.  CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients.

Authors:  Leila Amini; Dimitrios Laurin Wagner; Uta Rössler; Ghazaleh Zarrinrad; Livia Felicitas Wagner; Tino Vollmer; Désirée Jacqueline Wendering; Uwe Kornak; Hans-Dieter Volk; Petra Reinke; Michael Schmueck-Henneresse
Journal:  Mol Ther       Date:  2020-09-08       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.